Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env

Author(s): Scharf L, Wang H, Gao H, Chen S, McDowall AW, et al.

Abstract

The HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs); thus, most neutralizing antibodies are strain specific. The 8ANC195 epitope, defined by crystal and electron microscopy (EM) structures of bNAb 8ANC195 complexed with monomeric gp120 and trimeric Env, respectively, spans the gp120 and gp41 Env subunits. To investigate 8ANC195’s gp41 epitope at higher resolution, we solved a 3.58 Å crystal structure of 8ANC195 complexed with fully glycosylated Env trimer, revealing 8ANC195 insertion into a glycan shield gap to contact gp120 and gp41 glycans and protein residues. To determine whether 8ANC195 recognizes the CD4-bound open Env conformation that leads to co-receptor binding and fusion, one of several known conformations of virion-associated Env, we solved EM structures of an Env/CD4/CD4-induced antibody/8ANC195 complex. 8ANC195 binding partially closed the CD4-bound trimer, confirming structural plasticity of Env by revealing a previously unseen conformation. 8ANC195’s ability to bind different Env conformations suggests advantages for potential therapeutic applications.

Similar Articles

Trial, error and breakthrough: A review of HIV vaccine development

Author(s): Barry SM, Mena Lora AJ, Novak RM

Cell responses to HIV-1 infection and vaccination: pathways to preventing infection

Author(s): Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD

The antigenic structure of the HIV gp120 envelope glycoprotein

Author(s): Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al.

Crystal structure of a soluble cleaved HIV-1 envelope trimer

Author(s): Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer

Author(s): Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al.

Gene therapy as a vaccine for HIV-1

Author(s): Berkhout B, Sanders RW

Antibody gene transfer for HIV immunoprophylaxis

Author(s): Balazs AB, West AP

Rapamycin-regulated control of antiangiogenic tumor therapy following raav-mediated gene transfer

Author(s): Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, et al.

Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation

Author(s): Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, et al.

Novel targets for antiretroviral therapy

Author(s): Dau B, Holodniy M.

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine

Study record detail USA

Author(s): US National library of Medicine